Enterobiome
A microbiome company specializing in health functional foods and pharmaceuticals, utilizing next-generation probiotics derived from human gut microorganisms.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | KRW11.0b | Late VC | |
| Total Funding | 000k | ||
Related Content
Based in Goyang, South Korea, Enterobiome is a biotechnology firm established in May 2018 by Dr. Jae-Gu Seo. Dr. Seo, who holds a Ph.D. in microbiology and bacteriology, has focused on probiotics research and development since 2007, bringing a deep expertise in the human gut microbiome to lead the company's initiatives. The firm's core mission is to develop pharmabiotics, which are microbial-based biopharmaceutical products intended to treat and manage human diseases.
Enterobiome operates in the drug discovery and nutraceutical sectors, concentrating on the development of next-generation probiotics derived from the human gut microbiome. The company's business model involves creating microbiome treatments and health-functional foods aimed at addressing immune diseases, metabolic disorders like obesity and diabetes, aging-related conditions, and cancer. Revenue generation is pursued through the commercialization of these products, technical transfers, co-development partnerships, and licensing out its proprietary technologies. The company is also in the process of obtaining regulatory certifications in the United States and Korea to enter these markets.
The company's product development is centered on its extensive library of microbiome strains, including key species like Akkermansia muciniphila and Faecalibacterium prausnitzii. Enterobiome has developed original technology for the mass production of these strains. Its pipeline includes product candidates for various applications, with human testing completed for respiratory health and ongoing for body fat reduction, sensitive skin improvement, and hair loss. The company is also preparing for Phase 1 clinical trials for its microbiome-based medicines. In addition to therapeutic products, a separate entity offers "ENTEROBIOME" testing services, which analyze gut microbial composition to identify imbalances related to general health, pregnancy, menopause, and athletic performance.
Keywords: pharmabiotics, gut microbiome, probiotics, drug discovery, biotechnology, microbial-based therapeutics, metabolic disorders, immune diseases, Akkermansia muciniphila, Faecalibacterium prausnitzii, nutraceuticals, health-functional foods, microbiome testing, clinical trials, biopharmaceuticals, South Korea, Jae-Gu Seo, microbial library, mass production technology